Literature DB >> 6611107

Modeling metabolic processes in the brain in vivo.

L Sokoloff.   

Abstract

Positron emission tomography provides a means to measure local concentrations of positron-emitters in brain and to reconstruct pictorial images of the distribution of isotope in the brain. This capability is useful when the isotope is confined to a defined chemical species, and its concentration when combined with other measurable variables can be used to assay a physiological or biochemical process. Common variables are concentration and/or specific activity of the precursor tracer molecule in blood or plasma, the kinetics of exchange of the precursor molecule between blood and/or plasma and tissue, and the distribution space of the tracer in the tissue. These variables must be related, usually by an equation based on a kinetic model of the process under study. An example of such a method is the 2-deoxyglucose method which measures local rates of glucose utilization in brain. It was first developed with [14C]deoxyglucose and autoradiography in animals and has demonstrated a close relationship between local functional activity and glucose utilization in brain. It has proved useful to map regions of altered functional activity in the central nervous system in a variety of physiological and pharmacological states. By a combination of this technique with positron emission tomography and the positron-emitting analog, [18F]fluorodeoxyglucose, the method has been adapted for use in humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611107     DOI: 10.1002/ana.410150703

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

Review 1.  GluT4: A central player in hippocampal memory and brain insulin resistance.

Authors:  Ewan C McNay; Jiah Pearson-Leary
Journal:  Exp Neurol       Date:  2019-10-12       Impact factor: 5.330

2.  The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.

Authors:  Sterling C Johnson; Taylor W Schmitz; Mehul A Trivedi; Michele L Ries; Britta M Torgerson; Cynthia M Carlsson; Sanjay Asthana; Bruce P Hermann; Mark A Sager
Journal:  J Neurosci       Date:  2006-05-31       Impact factor: 6.167

3.  Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.

Authors:  Lisa Mosconi
Journal:  Clin Transl Imaging       Date:  2013-08

4.  Novel Roles for the Insulin-Regulated Glucose Transporter-4 in Hippocampally Dependent Memory.

Authors:  Jiah Pearson-Leary; Ewan C McNay
Journal:  J Neurosci       Date:  2016-11-23       Impact factor: 6.167

5.  Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.

Authors:  A Wolkin; B Angrist; A Wolf; J Brodie; B Wolkin; J Jaeger; R Cancro; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue.

Authors:  Y Mishima; Y Imahori; C Honda; J Hiratsuka; S Ueda; T Ido
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

7.  Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study.

Authors:  Mehul A Trivedi; Taylor W Schmitz; Michele L Ries; Britta M Torgerson; Mark A Sager; Bruce P Hermann; Sanjay Asthana; Sterling C Johnson
Journal:  BMC Med       Date:  2006-01-13       Impact factor: 8.775

Review 8.  Mental Work Requires Physical Energy: Self-Control Is Neither Exception nor Exceptional.

Authors:  Benjamin C Ampel; Mark Muraven; Ewan C McNay
Journal:  Front Psychol       Date:  2018-07-05

9.  APOE and Alzheimer's Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction.

Authors:  Jason A Brandon; Brandon C Farmer; Holden C Williams; Lance A Johnson
Journal:  Front Aging Neurosci       Date:  2018-06-14       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.